BFRI
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- Biofrontera submits an sNDA to the FDA to expand Ameluz red-light PDT to actinic keratoses across the full bodyOct 8, 2026
- FDA approved Ameluz Red Light PDT from Biofrontera for treating superficial basal cell carcinomaSep 15, 2026
- Biofrontera reported positive Phase 2b results supporting further development of Ameluz photodynamic therapy for moderate to severe acneMar 10, 2026
- Biofrontera reported positive Phase 3 results for Ameluz photodynamic therapy in actinic keratoses across extremities, neck, and trunk, meeting the primary endpointFeb 10, 2026
- Biofrontera Inc. announced database locks for two clinical studies supporting key milestonesJan 8, 2026